Amgen Inc. is moving ahead with a $650 million expansion of its biologics facility in Juncos, Puerto Rico, despite experiencing a 4% stock decline this week and holding a 72% strong sell rating from analysts. This initiative aims to create nearly 750 new jobs and reinforces the company's commitment to expanding its U.S. manufacturing capabilities. Notably, Amgen reported robust Q2 2025 results, with revenues up 9% year-over-year and a 92% increase in GAAP earnings per share, which helps sustain a positive outlook among analysts despite ongoing stock valuation concerns.
“Amgen (AMGN) stock · lost · 4% · current week”
“Amgen (AMGN) · is rated as · 72% Strong Sell · by the Barchart Technical Opinion indicator”
“Amgen (AMGN) stock · printed · 3-7-D sequence · in the past 10 weeks”
“the 3-7-D pathway under Amgen (AMGN) · has a 50th-percentile price of · $277.50”
“Enphase Energy (ENPH) stock · has a short interest of · 20% · of its float”
“Enphase Energy (ENPH) · printed · 6-4-D sequence · with an overall negative trajectory”
“Dutch Bros (BROS) stock · has gained · 1.37% · since the start of the year”
“Dutch Bros (BROS) · is rated as · 88% Strong Sell · by the Barchart Technical Opinion indicator”
“Dutch Bros (BROS) · printed · 3-7-D sequence · in the trailing 10 weeks”
“Amgen Inc. · is · one of the 12 Most Undervalued Dow Stocks to Buy According to Analysts · true”
“Amgen Inc. · is a · leading biotechnology company · true”
“Amgen Inc. · is specializing in · innovative therapeutics for complex cancers and serious illnesses · true”
